Source:http://linkedlifedata.com/resource/pubmed/id/19602710
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2009-9-18
|
| pubmed:databankReference | |
| pubmed:abstractText |
To evaluate internal tandem duplication (ITD) insertion sites and length as well as their clinical impact in younger adult patients with FLT3-ITD-positive acute myeloid leukemia (AML), sequencing after DNA-based amplification was performed in diagnostic samples from 241 FLT3-ITD-mutated patients. All patients were treated on 3 German-Austrian AML Study Group protocols. Thirty-four of the 241 patients had more than 1 ITD, leading to a total of 282 ITDs; the median ITD length was 48 nucleotides (range, 15-180 nucleotides). ITD integration sites were categorized according to functional regions of the FLT3 receptor: juxtamembrane domain (JMD), n = 148; JMD hinge region, n = 48; beta1-sheet of the tyrosine kinase domain-1 (TKD1), n = 73; remaining TKD1 region, n = 13. ITD length was strongly correlated with functional regions (P < .001). In multivariable analyses, ITD integration site in the beta1-sheet was identified as an unfavorable prognostic factor for achievement of a complete remission (odds ratio, 0.22; P = .01), relapse-free survival (hazard ratio, 1.86; P < .001), and overall survival (hazard ratio, 1.59; P = .008). ITD insertion site in the beta1-sheet appears to be an important unfavorable prognostic factor in young adult patients with FLT3-ITD-positive AML. The clinical trials described herein have been registered as follows: AML HD93 (already published in 2003), AML HD98A (NCT00146120; http://www.ClinicalTrials.gov), and AMLSG 07-04 (NCT00151242; http://www.ClinicalTrials.gov).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:BreitenbuecherFrankF,
pubmed-author:DöhnerHartmutH,
pubmed-author:DöhnerKonstanzeK,
pubmed-author:DuJuanJ,
pubmed-author:FischerThomasT,
pubmed-author:GanserArnoldA,
pubmed-author:German-Austrian AML Study Group (AMLSG),
pubmed-author:GronerSiljaS,
pubmed-author:KayserSabineS,
pubmed-author:KrauterJürgenJ,
pubmed-author:LondonoMartina CorreaMC,
pubmed-author:SchlenkRichard FRF,
pubmed-author:SpäthDanielaD,
pubmed-author:WittkeKerstinK
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
17
|
| pubmed:volume |
114
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2386-92
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:19602710-Adolescent,
pubmed-meshheading:19602710-Adult,
pubmed-meshheading:19602710-Aged,
pubmed-meshheading:19602710-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19602710-Chromatography, High Pressure Liquid,
pubmed-meshheading:19602710-Drug Resistance, Neoplasm,
pubmed-meshheading:19602710-Female,
pubmed-meshheading:19602710-Gene Duplication,
pubmed-meshheading:19602710-Humans,
pubmed-meshheading:19602710-Leukemia, Myeloid, Acute,
pubmed-meshheading:19602710-Male,
pubmed-meshheading:19602710-Middle Aged,
pubmed-meshheading:19602710-Mutagenesis, Insertional,
pubmed-meshheading:19602710-Mutation,
pubmed-meshheading:19602710-Polymerase Chain Reaction,
pubmed-meshheading:19602710-Prognosis,
pubmed-meshheading:19602710-Protein Structure, Tertiary,
pubmed-meshheading:19602710-Protein-Tyrosine Kinases,
pubmed-meshheading:19602710-Tandem Repeat Sequences,
pubmed-meshheading:19602710-Treatment Outcome,
pubmed-meshheading:19602710-fms-Like Tyrosine Kinase 3
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
|
| pubmed:affiliation |
Department of Internal Medicine III, University Hospital of Ulm, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|